PT. RICHMOND, Calif., Sept. 29 CA-Transcept-Pharm
PT. RICHMOND, Calif., Sept. 29 /PRNewswire/ -- Transcept Pharmaceuticals,
Inc., a privately-held specialty pharmaceutical company, announced today that
Glenn A. Oclassen, President and Chief Executive Officer, is scheduled to
present at the Third Annual JMP Healthcare Focus Conference in New York, NY on
Monday, October 6, 2008 at 4:30 PM Eastern Time.
An audio webcast of the presentation will be available at
http://www.wsw.com/webcast/jmp7/transcept/ and on the Transcept website at
http://www.transcept.com. The replay of the presentation will be available
for 30 days.
About Transcept Pharmaceuticals
Transcept Pharmaceuticals is a specialty pharmaceutical company focused on
the development and commercialization of proprietary products that address
important therapeutic needs in the fields of psychiatry and sleep medicine.
The lead Transcept product candidate, Intermezzo(R), is a sublingual low dose
formulation of zolpidem that has been developed for use as-needed for the
treatment of insomnia when a middle of the night awakening is followed by
difficulty returning to sleep.
Phase 3 clinical trials have been completed for Intermezzo(R) and
Transcept plans to submit a New Drug Application (NDA) to the U. S. Food and
Drug Administration (FDA) via the 505(b)(2) pathway prior to the end of 2008.
For further information, please visit the company's website at:
http://www.transcept.com.
Safe Harbor
This press release contains forward-looking statements for purposes of the
Private Securities Litigation Reform Act of 1995 (the "Act"). Transcept
disclaims any intent or obligation to update these forward-looking statements,
and claim the protection of the Safe Harbor for forward-looking statements
contained in the Act. Examples of such statements include, but are not
limited to, the expected timing of regulatory filings with respect to
Intermezzo(R) and the expected benefits of Transcept product candidates. Such
statements are based on management's current expectations, but actual results
may differ materially due to various risks and uncertainties, including, but
not limited to, Transcept product candidates may have unexpected adverse side
effects or inadequate therapeutic efficacy; positive results in clinical
trials may not be sufficient to obtain FDA approval; physician or patient
reluctance to use Intermezzo(R), if approved; potential alternative therapies;
maintaining adequate patent or trade secret protection without violating the
intellectual property rights of others; and other difficulties or delays in,
clinical development, obtaining regulatory approval, market acceptance and
commercialization of Transcept product candidates .
Contacts:
Transcept Pharmaceuticals, Inc.The Ruth Group
Michael Gill Investors / Media
Director of Communications Stephanie Carrington / Jason Rando
(510) 215-3575 (646) 536-7017 / 7025
mgill@transcept.comscarrington@theruthgroup.com
jrando@theruthgroup.com
SOURCE Transcept Pharmaceuticals, Inc.
